This is a working overview of SR9009, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-17. Anything still debated is marked as such rather than presented as settled.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
On 5 October, the 2025 Syrian parliamentary election was held in the temporary electoral system as an indirect vote, where only around 6,000 selected Syrians were eligible. 140 members were due to be elected by the electoral college, although only 119 were elected on election day due to postponement in select areas from security concerns. On 1 July, President Ahmed al-Sharaa appointed the remaining 70 additional members. The People's Assembly building underwent renovation by late 2025, the first since 2009, delaying the appointment of the 70 seats appointed by the president of Syria. While in at a meeting in the Royal Institute of International Affairs on 31 March 2026, al-Sharaa announced that the People's Assembly will be seated within the month. The first post-Assad People's Assembly was subsequently finalized in early July 2026, with its inaugural session originally scheduled for 6 July; however, a day before the scheduled date, the Higher Committee for People's Assembly Elections had announced that the inaugural session will be postponed to a later date. The inaugural session of the People's Assembly was held on 12 July 2026. At its second session, the Assembly passed a resolution setting up much of its internal procedures and structure; among the articles were provisions that the parliament cannot be dissolved by the President, must ratify international agreements and constitutional amendments, will broadcast its sessions publicly, and retains parliamentary immunity for its members only for when conducting parliamentary affairs.
The motor by Kelly and co-workers is an elegant example of how chemical energy can be used to induce controlled, unidirectional rotational motion, a process which resembles the consumption of ATP in organisms in order to fuel numerous processes. However, it does suffer from a serious drawback: the sequence of events that leads to 120° rotation is not repeatable. Kelly and co-workers have therefore searched for ways to extend the system so that this sequence can be carried out repeatedly. Unfortunately, their attempts to accomplish this objective have not been successful and currently the project has been abandoned. In 2016 David Leigh's group invented the first autonomous chemically-fuelled synthetic molecular motor. Some other examples of synthetic chemically driven rotary molecular motors that all operate by sequential addition of reagents have been reported, including the use of the stereoselective ring opening of a racemic biaryl lactone by the use of chiral reagents, which results in a directed 90° rotation of one aryl with respect to the other aryl. Branchaud and co-workers have reported that this approach, followed by an additional ring closing step, can be used to accomplish a non-repeatable 180° rotation.
== In transplant rejection == In a transplant procedure, as of an organ or stem cells, MHC molecules themselves act as antigens and can provoke immune response in the recipient, thus causing transplant rejection. MHC molecules were identified and named after their role in transplant rejection between mice of different strains, though it took over 20 years to clarify MHC's role in presenting peptide antigens to cytotoxic T lymphocytes (CTLs). Each human cell expresses six MHC class I alleles (one HLA-A, -B, and -C allele from each parent) and six to eight MHC class II alleles (one HLA-DP and -DQ, and one or two HLA-DR from each parent, and combinations of these). The MHC variation in the human population is high, at least 350 alleles for HLA-A genes, 620 alleles for HLA-B, 400 alleles for DR, and 90 alleles for DQ. Any two individuals who are not identical twins, triplets, or higher order multiple births, will express differing MHC molecules. All MHC molecules can mediate transplant rejection, but HLA-C and HLA-DP, showing low polymorphism, seem least important. When maturing in the thymus, T lymphocytes are selected for their TCR incapacity to recognize self antigens, yet T lymphocytes can react against the donor MHC's peptide-binding groove, the variable region of MHC holding the presented antigen's epitope for recognition by TCR, the matching paratope. T lymphocytes of the recipient take the incompatible peptide-binding groove as nonself antigen. There are various types of transplant rejection that are known to be mediated by MHC (HLA):
Breast cancer, which develops from breast tissue, is the most common cause of cancer death among women and a leading cause of general death among women. Factors that appear to be implicated in decreasing the risk of breast cancer are regular breast examinations by health care professionals, regular mammograms, self-examination of breasts, healthy diet, exercise to decrease excess body fat, and breastfeeding.
Sources: en.wikipedia.org
== Early years == Mariusz Pudzianowski was born in Biała Rawska, Poland. His father, Wojciech, was a weightlifter. Pudzianowski quickly became interested in sports. Since the age of 11, he has been training the Kyokushin style of karate. His current grade is 4th kyu green belt. He began strength training at the age of thirteen. When he was fifteen, Pudzianowski also started training boxing, quitting after seven years. Pudzianowski debuted in professional sports at the age of sixteen, taking part in Polish Weightlifting Championship, in the bench press event.
=== Energy conversion === Photocatalytic water splitting is an artificial photosynthesis process in which water is dissociated into hydrogen (H2) and oxygen (O2), using artificial or natural light. Methods such as photocatalytic water splitting are currently being investigated to produce hydrogen as a clean source of energy. The superior electron mobility and high surface area of graphene oxide sheets suggest it may be implemented as a catalyst that meets the requirements for this process. Specifically, graphene oxide's compositional functional groups of epoxide (-O-) and hydroxide (-OH) allow for more flexible control in the water splitting process. This flexibility can be used to tailor the band gap and band positions that are targeted in photocatalytic water splitting. Recent research experiments have demonstrated that the photocatalytic activity of graphene oxide containing a band gap within the required limits has produced effective splitting results, particularly when used with 40-50% coverage at a 2:1 hydroxide:epoxide ratio. When used in composite materials with CdS (a typical catalyst used in photocatalytic water splitting), graphene oxide nanocomposites have been shown to exhibit increased hydrogen production and quantum efficiency.
Theraflu (made by Novartis) — previously contained pseudoephedrine, now contains phenylephrine Trima — contains 60 mg pseudoephedrine hydrochloride Tylol Hot (made by NOBEL İLAÇ SANAYİİ VE TİCARET A.Ş., Turkey) — a packet of 20 g contains 60 mg pseudoephedrine hydrochloride, 500 mg paracetamol and 4 mg chlorpheniramine maleate Unifed (made by United Pharmaceutical Manufacturer, Jordan) — contains pseudoephedrine hydrochloride (also triprolidine and guaifenesin). Zyrtec-D 12 Hour (made by McNeil Consumer Healthcare, a Kenvue company) — contains 120 mg pseudoephedrine hydrochloride (also 5 mg of cetirizine). Zephrex-D (made by Westport Pharmaceuticals) – a special meth-resistant form of pseudoephedrine that becomes gooey when heated.
Sources: en.wikipedia.org
== Formation and decay == The sum of the atomic mass of the two atoms produced by the fission of one fissile atom is always less than the atomic mass of the original atom. This is because some of the mass is lost as free neutrons, and once kinetic energy of the fission products has been removed (i.e., the products have been cooled to extract the heat provided by the reaction), then the mass associated with this energy is lost to the system also, and thus appears to be "missing" from the cooled fission products. Since the nuclei that can readily undergo fission are particularly neutron-rich (e.g. 61% of the nucleons in uranium-235 are neutrons), the initial fission products are often more neutron-rich than stable nuclei of the same mass as the fission product (e.g. stable zirconium-90 is 56% neutrons compared to unstable strontium-90 at 58%). The initial fission products therefore may be unstable and typically undergo beta decay to move towards a stable configuration, converting a neutron to a proton with each beta emission. (Most fission products do not decay via alpha decay.) A few neutron-rich and short-lived initial fission products decay by ordinary beta decay (this is the source of perceptible half-life, typically a few tenths of a second to a few seconds), followed by immediate emission of a neutron by the excited daughter-product. This process is the source of so-called delayed neutrons, which play an important role in control of a nuclear reactor. The first beta decays are rapid and may release high energy beta particles or gamma radiation.
== Medical uses == Insulin degludec is indicated to improve glycemic control in people with diabetes. In a meta-analysis involving data from 3 randomized controlled trials having 1171 patients, thrice weekly insulin degludec had similar efficacy as daily insulin glargine injections with regards to the fasting blood glucose reduction, having similar safety and risk of low blood glucose (hypoglycaemia) profile. However the overall HbA1c reduction with thrice weekly insulin degludec injection was marginally lower than that of daily insulin glargine injections. Hence thrice weekly degludec injections can be considered in extremely needle prick phobic patients as a choice for basal insulin therapy.
Ghana lies on the Gulf of Guinea in West Africa, a few degrees north of the Equator. It covers 238,540 km2 (92,101 sq mi) and has an Atlantic coastline of about 560 kilometres (350 miles). It is situated between latitudes 4°45′N and 11°N, and longitudes 1°15′E and 3°15′W. The Prime Meridian passes through Tema, near Accra, making Ghana the country closest to the intersection of the Prime Meridian and the Equator (0°, 0°), located offshore in the Atlantic. Grasslands mixed with south coastal shrublands and forests dominate Ghana, with forest extending northward from the coast 320 kilometres (200 miles) and eastward for a maximum of about 270 kilometres (170 miles) with locations for mining of industrial minerals and timber. Ghana is home to five terrestrial ecoregions: Eastern Guinean forests, Guinean forest–savanna mosaic, West Sudanian savanna, Central African mangroves, and Guinean mangroves. The White Volta River and its tributary Black Volta, flow south through Ghana to Lake Volta, the world's third-largest reservoir by volume and largest by surface area, formed by the hydroelectric Akosombo Dam, completed in 1965. The Volta flows out of Lake Volta into the Gulf of Guinea. The northernmost part of Ghana is Pulmakong and the southernmost part of Ghana is Cape Three Points. Ghana consists of low coastal plains, forested hills in the centre, and savanna in the north.
Blast cell Blast cells are very immature cells that are normally found in the bone marrow, where they develop into mature cells (hematopoiesis) before being released into the blood. They can be identified by their large overall size, deep blue cytoplasm, and large nucleus with fine chromatin and prominent nucleoli. When seen on the blood smear, blast cells are an abnormal finding and may be indicative of acute leukaemia or other serious blood disorders. Rarely, they may be seen in severe cases of left shift. The presence of Auer rods inside blast cells indicates that they are of myeloid origin, which has important implications for leukaemia treatment. Other morphologic features can provide information about the lineage of blast cells: for example, myeloblasts tend to be large with distinct nucleoli, while lymphoblasts can be smaller with a denser chromatin pattern. However, these features are not diagnostic, and flow cytometry or special staining is generally used to confirm the lineage.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.